Abbott has secured approval from the US Food and Drug Administration (FDA) for its less-invasive heart pump implant procedure to help patients avoid open heart surgery.
With the approval, Abbott’s HeartMate 3 heart pump can be implanted in patients with advanced heart failure through an incision in the chest wall.
The device uses Full MagLev technology to reduce trauma to blood passing through the pump and improve outcomes for patients.
Abbott Mechanical Circulatory Support medical director Robert L Kormos said: “We continue to focus on advancing our heart failure devices and techniques to make life better for the patients we serve. The first approved LVAD HeartMate. It was approved more than 25 years ago. Since that time, the technology has evolved immensely.
“Today’s HeartMate 3 device, including its design and size, allows physicians to successfully implant it without having to perform open heart surgery and offers survival rates, as demonstrated in the MOMENTUM 3 clinical trial, at two-years that are comparable to heart transplants.”
Abbott claims that its new surgical technique will allow surgeons to choose the surgical method using its HeartMate 3 LVAD.
Through the alternative surgical technique, HeartMate 3 heart pump can be implanted through lateral thoracotomy, a surgical approach to access the heart through an incision between ribs.
The new less invasive surgical technique is said to be more effective than open heart surgery, resulting in less bleeding and shorter recovery time for many patients.
University of Rochester Medical Centre’s heart transplant surgeon Igor Gosev said: “This is a significant advancement for patients who can now receive a life-saving LVAD through an alternative procedure that can yield shorter hospital stays and a faster recovery.
“Heart failure is a crippling and costly disease so being able to offer patients the HeartMate 3 heart pump with this less-invasive approach gives them the opportunity to return to a better quality of life more quickly.”